News – Page 1134 – Endpoints News

Sucampo bags rare disease player Vtesse in $200M buyout agreement

9 years ago

Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal

9 years ago

#AACR17: Fresh from Merck embrace, fast-growing Incyte pivots into a PhIII IDO1/Opdivo tie-up with Bristol-Myers

9 years ago

Roche, Prothena hustle to PhII with their disease-modifying Parkinson's drug targeting alpha-synuclein

9 years ago

Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T, posts improved data

9 years ago

Promentis raises $26M for glutamatergic drug R&D; CARB-X offers up to $48M for fighting drug-resistant bacteria

9 years ago

Dems fire off a silly pricing bill; What's wrong with Novartis?

9 years ago

Halozyme slides on an early futility failure for its lead cancer therapy

9 years ago

Merck, Incyte map a Phase III pipeline of their own for a frontline combo of Keytruda and epacadostat

9 years ago

J&J pulls the plug on PhII study for NHL after Darzalex falls short

9 years ago

Fresh turmoil inside Novartis’ revamped CAR-T organization as top exec jumps ship

9 years ago

Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops

9 years ago

LAM raises $58M for cancer, rare disease pipeline; What do you pray for?

9 years ago

Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy

9 years ago

Corbus brags about another PhII success for its lead drug, but shares slide early

9 years ago

Hit with a trial failure, Agenus brings out the ax to chop staff, reorganize

9 years ago

Money, brains and ambition: Third Rock startup Tango launches with $55M and a stellar crew of scientific advisers

9 years ago

Novartis gets a speedy review for its CAR-T pioneer as FDA lines up a marketing decision

9 years ago

Blueprint maps plans for $150M raise; GlaxoSmithKline creates discovery pact with Warp Drive

9 years ago

FDA nomination in hand, Gottlieb prepares to disentangle himself from a long list of biopharma jobs and investments

9 years ago

With a new primary endpoint and the disappearance of a trial site, tiny Ritter claims a big clinical victory

9 years ago

Why wait? Trump mounts an early raid on NIH’s ’17 budget in search of some spending money

9 years ago

Megablockbuster day for Roche too as MS game-changer Ocrevus gets a green light at the FDA

9 years ago

Vertex shares surge as its cystic fibrosis combo proves marginally positive, but payers may not be so impressed

9 years ago

First page Previous page 1131 1132 113311341135 1136 1137 Next page Last page